Manager, Clinical Supply
Secura Bio
Manager, Clinical Supply
Secura Bio
Commercializes oncology therapies and develops COPIKTRA
Secura Bio was established in 2019 with a singular mission: to close the gap between innovative oncology therapies and the patients who need them most. Our high-touch approach is informed by our decades of experience shaping the impact of oncology’s largest clinical and market opportunities. We know that true impact comes from personalization and an unwavering commitment to serve patients and expand the possibilities of life-prolonging oncology medicines.
About the Role
We are seeking a talented and motivated Manager, Clinical Supply to join Secura Bio. The ideal candidate will lead the planning, execution, and oversight of clinical supply activities supporting global clinical development programs. The role is responsible for ensuring reliable product supply, coordinating cross-functional activities, and maintaining operational readiness across internal teams and external partners.
This role requires a high degree of ownership, responsiveness, and independent decision-making. The successful candidate will serve as a key liaison among Clinical Operations, Quality Assurance, Regulatory Affairs, contract manufacturers, depots, packaging vendors, and logistics providers. They will be expected to proactively identify and mitigate risks, communicate issues and priorities in a timely manner, and ensure continuity of clinical supply operations through effective planning and execution.
Employment Type
Full-time
Reports To
Senior Director, Technical Operations
Key Responsibilities
Required Qualifications
Preferred Qualifications
Salary
[]
Commercializes oncology therapies and develops COPIKTRA
Secura Bio is an integrated biopharmaceutical company focused on bringing oncology therapies to patients. Its main product is COPIKTRA (duvelisib), an oral PI3K inhibitor used to treat adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The company is also running a Phase 3 study of COPIKTRA for relapsed or refractory nodal T-follicular helper cell lymphoma. Secura Bio’s approach centers on acquiring, developing, and commercializing approved and late-stage oncology assets, with headquarters in Las Vegas and a European office in Dublin. In simple terms, the company buys or develops cancer drugs and then brings them to doctors and patients who need them. Its goal is to close the gap between available oncology therapies and the patients who can benefit from them.
Explore more opportunities at Secura Bio